Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 257Carcinoma, Intraductal, Noninfiltrating 24Breast Carcinoma In Situ 21Neoplasms 12Neoplasm Metastasis 12Breast Neoplasms, Male 12Ovarian Neoplasms 10Inflammatory Breast Neoplasms 7Glioblastoma 6Prostatic Neoplasms 5Endometrial Neoplasms 5Central Nervous System Neoplasms 5Gliosarcoma 4Fallopian Tube Neoplasms 4Breast Cancer Female 4Brain Neoplasms 4Glioma 3Carcinoma, Ovarian Epithelial 3Carcinoma, Ductal, Breast 3Breast Diseases 3Astrocytoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma 2Recurrence 2Pancreatic Neoplasms 2Oligodendroglioma 2Medulloblastoma 2Liver Neoplasms 2Hot Flashes 2

Interventions

endostar protein 1coenzyme Q10 1apatinib 1Yoga 1Ubiquinone 1Tamoxifen 1Referral and Consultation 1Palliative Care 1Oxaliplatin 1Melatonin 1Gardening 1Exercise 1Educational Status 1Diet Therapy 1Chemoradiotherapy 1Capecitabine 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Quality of Life × Tamoxifen × Clear all
NCT00784680 2009-05-01

ATAC - Quality of Life Sub-Protocol

AstraZeneca

Phase 3 Completed
308 enrolled

Quality of Life

Data powered by HemOnc (CC BY 4.0) Colophon âš¡